|
Vaccine Detail
Lassa fever Virus DNA Vaccine encoding GPC gene of LASV (Josiah Strain) |
Vaccine Information |
- Manufacturer: United States Army Medical Research Institute of Infectious diseases (USAMRIID)
- Type: DNA vaccine
- Status: Research
- Host Species for Licensed Use: None
- Antigen: Lassa Virus (Josiah Strain) GPC Gene (Cashman et al., 2017)
- GPC [Mopeia Lassa virus reassortant 29]
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Preparation: GPC gene of LASV with post-translational cleavage of GPC into GP1 and GP2 in the host. (Cashman et al., 2017)
- Immunization Route: Intradermal injection (i.d.)
|
Host Response |
Macaque Response
- Vaccination Protocol: Cynomolgus macaques (NHP) were vaccinated by intradermal (ID) injection of the vaccine followed by ID-electroporation (EP). . Two separate studies were conducted to com- pare 3 or 2 vaccinations at 4-week intervals. (Cashman et al., 2017)
- Immune Response: Following exposure to LASV, neutralizing antibody levels increased in the LASV DNA-vaccinated NHP, peaking approximately 21 d post exposure, then declining slightly at the study end point. Initially, white blood cells (WBC) increased in the LASV DNA-vaccinated. Lymphocyte and monocyte populations increased rapidly after exposure in the LASV DNA-vaccinated NHP, stabilizing by day 21. Both hemoglobin and hematocrit increased before becoming stable in the LASV DNA-vaccinated NHP. Platelets increased in the LASV DNA-vaccinated NHP. (Cashman et al., 2017)
- Challenge Protocol: LASV Challenge
- Efficacy: To identify virus levels in the blood post-exposure, serum viremia was measured using a standard plaque assay as described. Neither serum viremia nor fever was observed in any of the LASV DNA-vaccinated NHP at any time-point. One NHP had one plaque present at the 1 £ 10¡1 dilution at day 6 which falls below the limit of quantitation for the assay and is considered a false positive. (Cashman et al., 2017)
- Description: All LASV-GPC DNA-vaccinated NHP, regardless of dose group, showed no signs of infection after exposure and survived to the study end point. Final morbidity scores were assigned at the study end point. A score of zero indicated the macaque was well; showing no outward signs of disease; whereas, a score of 10 indicated the NHP was severely ill and met euthanasia criteria. The LASV DNA-vaccinated NHP remained at zero on the morbidity scale for the duration of the study. (Cashman et al., 2017)
|
References |
|
|